2021
Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity?
Zheng Y, Cai M, Li E, Fang W, Shen C, Zhang Y. Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity? Frontiers In Immunology 2021, 12: 671425. PMID: 34220818, PMCID: PMC8249196, DOI: 10.3389/fimmu.2021.671425.Peer-Reviewed Original ResearchConceptsMyelin oligodendrocyte glycoproteinMultiple sclerosisMyelin oligodendrocyte glycoprotein-antibody testingClinical phenotypeConus medullaris involvementUnder-recognized entityProportion of patientsSteroid-dependentMedullary involvementOligodendrocyte glycoproteinMOGADRadiological manifestationsRecurrent episodesTherapeutic responseDisease courseAntibody seropositivityUnder-recognizedPatientsAntibody testMyelitisSclerosisSeropositivityMyelinManifestationsPhenotype
2020
HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window
Zhao J, Zheng Y, Liu K, Chen J, Lai N, Fei F, Shi J, Xu C, Wang S, Nishibori M, Wang Y, Chen Z. HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window. Neurotherapeutics 2020, 17: 710-721. PMID: 31802434, PMCID: PMC7283397, DOI: 10.1007/s13311-019-00815-3.Peer-Reviewed Original ResearchConceptsHigh mobility group box 1Anti-HMGB1 mAbStatus epilepticusTherapeutic targetLife-threatening neurological emergencyToll-like receptor 4 (TLR4)-dependent pathwayAnti-HMGB1 monoclonal antibodyNeutralization of HMGB1Plasma HMGB1 levelsMobility group box 1Severity of seizure activityExogenous high mobility group box 1Incidence of SENonrefractory SEHMGB1 levelsPredictive biomarkersTherapeutic responseNeurological emergencyTherapeutic windowBox 1Seizure activityMonoclonal antibodiesPharmacological therapeuticsSE periodEpilepticus